{
    "nctId": "NCT04150731",
    "briefTitle": "16\u03b1-18F-fluor-17\u03b2-estradiol PET/CT for Visualisation of Estrogen Receptor Positive Liver Metastases From Breast Cancer",
    "officialTitle": "16\u03b1-18F-fluor-17\u03b2-\u00f8stradiol PET/CT Til Visualisering af \u00f8strogenreceptor-positive Levermetastaser Fra brystkr\u00e6ft",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 8,
    "primaryOutcomeMeasure": "Sensitivity of parametric FES-PET/CT",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with known disseminated breast cancer\n* Metastatic ER+ HER2- breast cancer with metastases in the liver, at least two separate liver foci visualised on CT\n* Diagnostic CT scan done in connection with clinical control\n* Treatment with aromatase inhibitors, and potential additional treatment\n* Postmenopausal\n\nExclusion Criteria:\n\n* Treatment with Tamoxifen or Fulvestrant completed within 5 weeks prior to FES-PET/CT\n* ER- metastases\n* Life expectancy under three months\n* Claustrophobia\n* Any pain which makes it impossible to lie in the scanner for 90 minutes",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}